Company Overview of Juno Therapeutics Inc.
Juno Therapeutics Inc., a biotechnology company, develops immunotherapy platforms for the treatment of cancer. Its immunotherapy platforms include chimeric antigen receptors, which target cell surface tumor-associated antigens that are expressed on cancer cells; and T-cell receptors, the molecules that are utilized by T-cells to recognize target antigens, as well as detect alterations in intracellular antigens present in cancer cells. The company was incorporated in 2013 and is based in Seattle, Washington.
307 Westlake Avenue North
Seattle, WA 98109
Founded in 2013
Key Executives for Juno Therapeutics Inc.
Juno Therapeutics Inc. Key Developments
Similar Private Companies By Industry
|Cogenics Icoria, Inc.||United States|
|Symphony Dynamo, Inc.||United States|
|Nebraska Cultures, Inc.||United States|
|ThermoGen, Inc.||United States|
|Soluble Therapeutics, LLC||United States|
Recent Private Companies Transactions
April 24, 2014
December 3, 2013
To contact Juno Therapeutics Inc., please visit junotherapeutics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.